Zheng Quan Zhi Xing·2025-08-15 16:35Summary of Key Points Core Viewpoint The report provides a detailed account of the fundraising activities and the actual usage of the raised funds by Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. for the first half of 2025, ensuring compliance with regulatory requirements and transparency in financial management. Group 1: Fundraising Overview - The company raised a total of approximately 7.89 billion RMB through a non-public offering of 334,711,699 shares at a price of 23.56 RMB per share, with a net amount of approximately 7.86 billion RMB after deducting issuance costs [1][2]. - The funds were verified by an accounting firm, and the report includes a verification report number [1]. Group 2: Fund Usage and Current Balance - As of June 30, 2025, the total amount of raised funds used was approximately 766,170.29 million RMB, with a remaining balance of approximately 41,839.21 million RMB in dedicated accounts [2][3]. - The company has established dedicated accounts at various banks to manage the raised funds, ensuring proper oversight and compliance with regulations [3][4]. Group 3: Fund Management and Compliance - The company has implemented a fundraising management method to regulate the use of raised funds and protect investor interests, which was approved by the shareholders [2][4]. - There were no instances of using idle funds for temporary working capital or investing in financial products during the reporting period [6][12]. Group 4: Project Investment and Changes - The total investment in fundraising projects amounted to approximately 766,170.29 million RMB, including pre-investments from self-raised funds [6][10]. - The company has made changes to the use of funds for specific projects, including reallocating funds for the acquisition of trademarks and construction projects, with all changes approved by the board and disclosed appropriately [8][9][10]. Group 5: Project Status and Future Plans - Several projects funded by the raised capital are either completed or in the operational phase, with ongoing assessments of their financial returns [12][14]. - The company has not reported any significant delays or changes in the feasibility of the projects funded by the raised capital [12][14].